Session proposals congress 2020

Below you will find information on session proposal deadlines, priority topics and session types.

For questions regarding the scientific and educational programme, please contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

Session proposal tips

Please go through these tips before submitting a session proposal.

 

Session proposal deadlines

Submission for Vienna Congress 2020 is now closed.

1st round session submission for Barcelona Congress 2021 will be opened from 27 June 2020 to 7 September 2021. Please check more details https://erscongress.org/programme-2020/session-proposal-2021.

 

Symposia priority topics for ERS Congress 2020

The ERS Congress 2020 programme theme selected by our Congress Chairs is: "Respiratory diseases and their origins in early life".

The programme will also cover the most recent topics on research and clinical practice, including:

Assembly Topics
1 - General pneumology
  • Pulmonary rehabilitation - including telemedicine
  • Pulmonary involvement in systemic and other conditions
  • Multimorbidity management
  • Non-pharmacological management of interstitial lung diseases
  • Integration of m-health and e-health
2 - Respiratory intensive care
  • NIV and sedation
  • Personalized medicine in ARDS
  • Management of difficult-to-wean patients
  • Chronic NIV and home mechanical ventilation
  • Sepsis
3 - Basic and translational sciences
  • Lung microenvironment: implications for chronic lung disease
  • Human ex vivo models
  • Damage and repair of the epithelium
  • Cell-matrix interactions in lung disease and regeneration
  • Epigenetic/genetic-environment interactions
4 - Sleep and breathing disorders; and clinical physiology
  • Control of breathing – hypoventilation during sleep, exercise and dyspnoea
  • Sleep apnoea
  • Big data and machine learning in respiratory and sleep pathophysiology
  • Exercise and sleep: from impaired function to new therapeutic strategies
  • Hypoxia: protective and harmful mechanisms from wakefulness to sleep
  • Asymptomatic OSA
5 - Airway diseases, asthma and COPD
  • Novel immunology-based therapies in asthma and COPD / Treatment of severe asthma
  • Asthma and COPD exacerbations / Treatment & prevention of airway disease exacerbations
  • COPD: Pharmacological management
  • Precision medicine in airway diseases: from bench to bedside
  • Multi-disciplinary interactions to treat airway diseases
6 - Epidemiology and environment
  • Occupational and environmental contributions including tobacco to airway disease burden
  • Occupational and environmental contributions including tobacco to interstitial lung disease and respiratory cancers
  • Air pollution
  • Genetic and environmental contribution including tobacco to disease causation since early life
  • Risk prediction in early life for chronic respiratory disease and other NCDs
7 - Paediatrics
  • Evidence based clinical practice guideline on the diagnosis of asthma in children aged 5 to 16 years
  • Asthma
  • Lung development and aging
  • Acute and chronic cough
  • Infectious agents in childhood asthma
8 - Thoracic surgery and transplantation
  • Lung transplantation in the era of new drugs
  • Lung cancer screening. What to do next?
  • Bronchiectasis
  • Tuberculosis
  • Standardizing definitions and outcome measures in acute bronchiolitis
9 - Allied respiratory professionals
  • Utilizing exercise testing in pre-operative assessment, rehabilitation and exercise prescription
  • Psychological wellbeing and prevention of psychological distress in chronic lung diseases
  • Functional evaluation of lung and airways: building a flow chart for a comprehensive, multifaceted, evidence-based use of the different techniques
  • A hands-off (non-invasive) approach to respiratory assessment
  • Interdisciplinary assessment and management of ILD (DPLD)
  • Frailty in chronic lung disease
10 - Respiratory infections
  • Management of tuberculosis
  • The future of inhaled antibiotics in respiratory diseases
  • Can we improve the immune response against respiratory infections?
  • Results of new trials in Tuberculosis
  • Point of care diagnostics for respiratory infections
11 - Thoracic oncology
  • Immunotherapies for lung cancer
  • Implementation of thoracic malignancies management: from RCT's to real life data
  • When the nodules are suspicious
  • Complications of therapy in thoracic malignancies
  • Lung cancer and ILD: gens, environments, drugs
  • Oligometastatic & oligoprogressive diseases
12 - Interstitial lung diseases
  • Thoracic complications of connective tissue diseases
  • Acute exacerbation in ILD
  • Sarcoidosis treatment
  • Autoimmunity across ILD
  • IPF & "Friends" – the concept of PF-ILD
13 - Pulmonary vascular diseases
  • When the lung vessels do matter
  • From clinical observation to pathobiological insight in pulmonary vascular diseases
  • Three months later: post pulmonary embolism syndrome and prevention of VTE recurrence
  • Answer to practical questions for PE patients: Do I need a thrombophilia testing?, Do I have a cancer?, Do I need anticoagulation for my (small) subsegmental PE?, Do I need treatment for my (asymptomatic) incidental PE?
  • Interventional treatment of high-risk pulmonary embolism
14 - Clinical techniques, imaging and endoscopy
  • Patient related outcomes of interventional pulmonology procedures
  • Interaction chest radiology - pulmonology
  • ERS meets European Society of Thoracic Imaging (interstitial lung disease)
  • Imaging of chest
  • Thoracic ultrasound

* Topics last updated: June 2019

 The ERS Congress Programme Committee encourages you to develop a session that includes faculty members of varying ages, backgrounds, specialties and gender. The congress theme should also be reflected in session proposals as much as possible.

 

 


Copyright © 2020 - ERS International Congress - European Respiratory Society. All Rights Reserved.